| scholarly article | Q13442814 |
| P2093 | author name string | Darrell J Irvine | |
| Matthias T Stephan | |||
| P2860 | cites work | Targeting quantum dots to surface proteins in living cells with biotin ligase | Q24527307 |
| Noninvasive detection of therapeutic cytolytic T cells with 18F-FHBG PET in a patient with glioma | Q24598366 | ||
| Bioresponsive matrices in drug delivery | Q24629097 | ||
| Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells | Q24651232 | ||
| Cancer regression in patients after transfer of genetically engineered lymphocytes | Q24654976 | ||
| Copper-free click chemistry for dynamic in vivo imaging | Q24675560 | ||
| Adoptive T cell therapy for cancer in the clinic | Q24680405 | ||
| Engineering chemical reactivity on cell surfaces through oligosaccharide biosynthesis | Q28239786 | ||
| Ex vivo glycan engineering of CD44 programs human multipotent mesenchymal stromal cell trafficking to bone | Q28264546 | ||
| Chemical remodelling of cell surfaces in living animals | Q28277825 | ||
| In vivo imaging of membrane-associated glycans in developing zebrafish | Q28278605 | ||
| Induced pluripotent stem cells offer new approach to therapy in thalassemia and sickle cell anemia and option in prenatal diagnosis in genetic diseases | Q37239088 | ||
| The impact of PEGylation on biological therapies | Q37263179 | ||
| Applications of lentiviral vectors for shRNA delivery and transgenesis | Q37347170 | ||
| Safety and immunologic effects of IL-15 administration in nonhuman primates | Q37352474 | ||
| Enzyme-triggered disassembly of dendrimer-based amphiphilic nanocontainers | Q37380048 | ||
| Mesenchymal stem cell homing: the devil is in the details | Q37407769 | ||
| Measuring Receptor-Ligand Binding Kinetics on Cell Surfaces: From Adhesion Frequency to Thermal Fluctuation Methods. | Q37408990 | ||
| Engineering artificial antigen-presenting cells to express a diverse array of co-stimulatory molecules. | Q37599553 | ||
| PEGylation for improving the effectiveness of therapeutic biomolecules. | Q37643474 | ||
| Endocytosis unplugged: multiple ways to enter the cell | Q37686075 | ||
| DNA-incorporating nanomaterials in biotechnological applications | Q37690699 | ||
| PEGylated polymers for medicine: from conjugation to self-assembled systems | Q37693784 | ||
| Nanoparticles for tumor targeted therapies and their pharmacokinetics | Q37722776 | ||
| Nanocarriers: a general strategy for enhancement of oral bioavailability of poorly absorbed or pre-systemically metabolized drugs | Q37729240 | ||
| Newly emerging roles for prostaglandin E2 regulation of hematopoiesis and hematopoietic stem cell engraftment | Q37753838 | ||
| Aptamer applications for targeted cancer therapy | Q37771956 | ||
| Concise review: Nanoparticles and cellular carriers-allies in cancer imaging and cellular gene therapy? | Q37772453 | ||
| Nanomedicine: magnetic nanoparticles and their biomedical applications | Q37772525 | ||
| Poly(ethylene glycol) in drug delivery: pros and cons as well as potential alternatives | Q37774596 | ||
| Immune regulatory antibodies: are they the next advance? | Q37778691 | ||
| Umbilical cord blood stem cells: what to expect | Q37788736 | ||
| Regulation of protein turnover by longevity pathways | Q37795736 | ||
| Mesenchymal stromal cells for graft-versus-host disease : basic aspects and clinical outcomes | Q37814791 | ||
| Advancement in carbon nanotubes: basics, biomedical applications and toxicity. | Q37828625 | ||
| Targeted delivery of progenitor cells for cartilage repair. | Q38478621 | ||
| Cell-surface engineering with GPI-anchored proteins. | Q38507407 | ||
| Nanoparticulate cellular patches for cell-mediated tumoritropic delivery | Q39564643 | ||
| Changes of cell-surface thiols and intracellular signaling in human monocytic cell line THP-1 treated with diphenylcyclopropenone | Q39622703 | ||
| Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha | Q39635625 | ||
| Effect of nanoparticle surface charge at the plasma membrane and beyond | Q39695379 | ||
| Modification of cell-surface thiols elicits activation of human monocytic cell line THP-1: possible involvement in effect of haptens 2,4-dinitrochlorobenzene and nickel sulfate | Q39865829 | ||
| In situ regulation of DC subsets and T cells mediates tumor regression in mice | Q39885761 | ||
| Mesenchymal stem cell transplantation in amyotrophic lateral sclerosis: A Phase I clinical trial | Q39955188 | ||
| Dendritic cells and T cells deliver oncolytic reovirus for tumour killing despite pre-existing anti-viral immunity | Q39995496 | ||
| Tumor-targeted, systemic delivery of therapeutic viral vectors using hitchhiking on antigen-specific T cells | Q40371833 | ||
| Multifunctional nanoarchitectures from DNA-based ABC monomers. | Q40385142 | ||
| Selective cell attachment to a biomimetic polymer surface through the recognition of cell-surface tags. | Q40422048 | ||
| Site-specific labeling of cell surface proteins with biophysical probes using biotin ligase | Q40443805 | ||
| Engineered mesenchymal stem cells with self-assembled vesicles for systemic cell targeting | Q40734038 | ||
| Recombinant interleukin 2 toxicity, pharmacokinetics, and immunomodulatory effects in a phase I trial | Q40794891 | ||
| Hierarchical costimulator thresholds for distinct immune responses: application of a novel two-step Fc fusion protein transfer method | Q40908075 | ||
| Control of HIV-1 immune escape by CD8 T cells expressing enhanced T-cell receptor | Q41410840 | ||
| A synthetic mimic of human Fc receptors: defined chemical modification of cell surfaces enables efficient endocytic uptake of human immunoglobulin-G. | Q41763223 | ||
| Surface Properties Dictate Uptake, Distribution, Excretion, and Toxicity of Nanoparticles in Fish | Q42264179 | ||
| Cell-based therapeutics from an economic perspective: primed for a commercial success or a research sinkhole? | Q42698545 | ||
| Synthesis of an artificial cell surface receptor that enables oligohistidine affinity tags to function as metal-dependent cell-penetrating peptides | Q42751853 | ||
| Polyelectrolyte nano-scaffolds for the design of layered cellular architectures | Q42798896 | ||
| Engineering novel cell surface receptors for virus-mediated gene transfer | Q42812913 | ||
| Cancer. Awakening immunity | Q42836312 | ||
| Directing Stem Cell Trafficking via GPS | Q42917963 | ||
| Nucleic acid aptamers for target validation and therapeutic applications | Q43076601 | ||
| Noncovalent cell surface engineering with cationic graft copolymers | Q43229850 | ||
| Prolonged circulation of large polymeric nanoparticles by non-covalent adsorption on erythrocytes | Q43441843 | ||
| Antibody targeting of stem cells to infarcted myocardium. | Q43501355 | ||
| Kinetic parameters for small-molecule drug delivery by covalent cell surface targeting | Q43828756 | ||
| Cell membrane modification for rapid display of proteins as a novel means of immunomodulation: FasL-decorated cells prevent islet graft rejection | Q44247187 | ||
| Nanocoatings onto arteries via layer-by-layer deposition: toward the in vivo repair of damaged blood vessels | Q44481738 | ||
| A novel approach to cancer immunotherapy: tumor cells decorated with CD80 generate effective antitumor immunity | Q44521091 | ||
| Rewiring cell adhesion. | Q44909060 | ||
| Gene therapy to improve function of T cells for adoptive immunotherapy. | Q44989576 | ||
| Surface fucosylation of human cord blood cells augments binding to P-selectin and E-selectin and enhances engraftment in bone marrow | Q44997562 | ||
| Preparation and characterisation of antibody modified gelatin nanoparticles as drug carrier system for uptake in lymphocytes | Q45178049 | ||
| Interfacing carbon nanotubes with living cells | Q46042504 | ||
| Getting to the site of inflammation: the leukocyte adhesion cascade updated | Q29547271 | ||
| Mechanisms of endocytosis | Q29547609 | ||
| Mesenchymal stem cells in health and disease | Q29614296 | ||
| Nanoparticle therapeutics: an emerging treatment modality for cancer | Q29615628 | ||
| Lipid rafts as a membrane-organizing principle | Q29615727 | ||
| Treatment of sickle cell anemia mouse model with iPS cells generated from autologous skin | Q29619238 | ||
| Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment | Q30415355 | ||
| Role of target geometry in phagocytosis | Q30477258 | ||
| Development of a macrophage-based nanoparticle platform for antiretroviral drug delivery | Q30479638 | ||
| Targeting mesenchymal stem cells to activated endothelial cells | Q30488087 | ||
| Noncovalent cell surface engineering: incorporation of bioactive synthetic glycopolymers into cellular membranes | Q30489461 | ||
| The regulatory role of cell mechanics for migration of differentiating myeloid cells | Q30490345 | ||
| Direct cell surface modification with DNA for the capture of primary cells and the investigation of myotube formation on defined patterns | Q30492908 | ||
| Candidate genes for expansion and transformation of hematopoietic stem cells by NUP98-HOX fusion genes | Q33294832 | ||
| Human erythrocytes selectively bind and enrich infectious HIV-1 virions | Q33518534 | ||
| Control of endothelial targeting and intracellular delivery of therapeutic enzymes by modulating the size and shape of ICAM-1-targeted carriers | Q33606794 | ||
| Can cells and biomaterials in therapeutic medicine be shielded from innate immune recognition? | Q33636425 | ||
| Notch-mediated expansion of human cord blood progenitor cells capable of rapid myeloid reconstitution | Q33642298 | ||
| Surface engineering of macrophages with nanoparticles to generate a cell-nanoparticle hybrid vehicle for hypoxia-targeted drug delivery | Q33644844 | ||
| Engineering an antibody with picomolar affinity to DOTA chelates of multiple radionuclides for pretargeted radioimmunotherapy and imaging | Q33661948 | ||
| Review article: current status of myocardial regeneration: new cell sources and new strategies | Q33753657 | ||
| Inhibitors of B7-CD28 costimulation in urologic malignancies | Q33827752 | ||
| Mechanics of receptor-mediated endocytosis | Q33892369 | ||
| pH-sensitive multi-PEGylated block copolymer as a bioresponsive pDNA delivery vector | Q34050052 | ||
| Drug targeting | Q34061195 | ||
| Macrophages: master regulators of inflammation and fibrosis | Q34076279 | ||
| Therapeutic cell engineering with surface-conjugated synthetic nanoparticles | Q34112602 | ||
| Pancreatic stem/progenitor cells for the treatment of diabetes. | Q34148810 | ||
| Dendritic Cell‐Based Immunotherapy for Prostate Cancer | Q34284652 | ||
| Biomaterial-associated thrombosis: roles of coagulation factors, complement, platelets and leukocytes | Q34321308 | ||
| Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy. | Q34422330 | ||
| Internalizing antibodies are necessary for improved therapeutic efficacy of antibody-targeted liposomal drugs. | Q34530035 | ||
| Safety and immunological effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and amyotrophic lateral sclerosis | Q34564111 | ||
| Cellular and extracellular programming of cell fate through engineered intracrine-, paracrine-, and endocrine-like mechanisms | Q34596348 | ||
| Antibody-drug conjugates: targeted drug delivery for cancer | Q34621670 | ||
| A cellular Trojan Horse for delivery of therapeutic nanoparticles into tumors. | Q34708838 | ||
| Redirecting lipoic acid ligase for cell surface protein labeling with small-molecule probes. | Q34721966 | ||
| The glycosylphosphatidylinositol anchor: a complex membrane-anchoring structure for proteins | Q34786761 | ||
| The systematic production of cells for cell therapies | Q34861981 | ||
| Lymphocyte surface thiol levels | Q34920137 | ||
| A2A adenosine receptor protects tumors from antitumor T cells. | Q35016529 | ||
| Carrier erythrocytes: an overview | Q35055323 | ||
| Prostaglandin E2 enhances human cord blood stem cell xenotransplants and shows long-term safety in preclinical nonhuman primate transplant models. | Q35140717 | ||
| Occurrence of leukaemia following gene therapy of X-linked SCID. | Q35166805 | ||
| Chemistry and material science at the cell surface. | Q35170330 | ||
| Metabolic oligosaccharide engineering as a tool for glycobiology | Q35568888 | ||
| Ligand-clustered "patchy" nanoparticles for modulated cellular uptake and in vivo tumor targeting | Q36141137 | ||
| Gene therapy: twenty-first century medicine | Q36161193 | ||
| Transmembrane helices before, during, and after insertion | Q36206950 | ||
| Lymphocyte membrane dynamics. Metabolic release of cell surface proteins | Q36271338 | ||
| Synthetic mimics of mammalian cell surface receptors: prosthetic molecules that augment living cells | Q36279826 | ||
| Erythrocyte-based drug delivery. | Q36316729 | ||
| Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles | Q36319725 | ||
| New frontiers in the therapeutic management of transplant rejection | Q36536440 | ||
| Pharmacytes: an ideal vehicle for targeted drug delivery | Q36627083 | ||
| IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapy | Q36677310 | ||
| Tumor microenvironment abnormalities: causes, consequences, and strategies to normalize | Q36685235 | ||
| Applications of carrier erythrocytes in delivery of biopharmaceuticals | Q36725488 | ||
| Wall shear stress: theoretical considerations and methods of measurement | Q36747674 | ||
| Mesenchymal stem cells: a new strategy for immunosuppression? | Q36776872 | ||
| Transforming growth factor-beta receptor blockade augments the effectiveness of adoptive T-cell therapy of established solid cancers | Q36801053 | ||
| Imaging the Beta-cell mass: why and how | Q36839324 | ||
| Potential clinical applications of quantum dots | Q36857644 | ||
| Clinical strategies to enhance T cell reconstitution | Q36983263 | ||
| Preclinical studies to understand nanoparticle interaction with the immune system and its potential effects on nanoparticle biodistribution | Q37036373 | ||
| Targeting vault nanoparticles to specific cell surface receptors | Q37094289 | ||
| PEGylation as a tool for the biomedical engineering of surface modified microparticles | Q37096668 | ||
| Taming the Trojan horse: optimizing dynamic carrier cell/oncolytic virus systems for cancer biotherapy | Q37120166 | ||
| Boron nitride nanotubes are noncytotoxic and can be functionalized for interaction with proteins and cells. | Q37131722 | ||
| The utility of cells as vehicles for oncolytic virus therapies. | Q37236085 | ||
| Chemical engineering of mesenchymal stem cells to induce a cell rolling response | Q46273539 | ||
| Long circulating nanoparticles via adhesion on red blood cells: mechanism and extended circulation. | Q46417574 | ||
| Very slow turnover of beta-cells in aged adult mice | Q46670100 | ||
| Metabolic installation of thiols into sialic acid modulates adhesion and stem cell biology | Q46941328 | ||
| Nanoparticle-mediated cellular response is size-dependent. | Q47223945 | ||
| Programmed death 1 signaling on chronic myeloid leukemia-specific T cells results in T-cell exhaustion and disease progression | Q47867798 | ||
| Allogeneic haematopoietic stem cell transplantation: individualized stem cell and immune therapy of cancer | Q48881552 | ||
| A nanoscopic multivalent antigen-presenting carrier for sensitive detection and drug delivery to T cells. | Q51040710 | ||
| A new strategy toward improving immunoprotection in cell therapy for diabetes mellitus: long-functioning PEGylated islets in vivo. | Q51236697 | ||
| Generation of GPI-linked CCL5 based chemokine receptor antagonists for the suppression of acute vascular damage during allograft transplantation. | Q51812874 | ||
| Biosynthesis of a nonphysiological sialic acid in different rat organs, using N-propanoyl-D-hexosamines as precursors | Q53025420 | ||
| Next generation adoptive immunotherapy--human T cells as carriers of therapeutic nanoparticles. | Q53497376 | ||
| Mesenchymal lineage precursor cells induce vascular network formation in ischemic myocardium. | Q53635005 | ||
| Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15. | Q53659254 | ||
| Release of vitamin B12 from carrier erythrocytes in vitro. | Q53720253 | ||
| Combined effects of Notch signaling and cytokines induce a multiple log increase in precursors with lymphoid and myeloid reconstituting ability. | Q54393655 | ||
| Uptake and intracellular distribution of silver nanoparticles in human mesenchymal stem cells | Q56483169 | ||
| Multifunctional superparamagnetic nanocarriers with folate-mediated and pH-responsive targeting properties for anticancer drug delivery | Q57185379 | ||
| Antibody Targeting of Long-Circulating Lipidic Nanoparticles Does Not Increase Tumor Localization but Does Increase Internalization in Animal Models | Q62100948 | ||
| Blood coagulation on biomaterials requires the combination of distinct activation processes | Q62659578 | ||
| Cell surface lipids and adhesion: III. the effects on cell adhesion of changes in plasmalemmal lipids | Q67249813 | ||
| Altered fatty acid membrane composition modifies lymphocyte localization in vivo | Q69897577 | ||
| The use of palmitate-conjugated protein A for coating cells with artificial receptors which facilitate intercellular interactions | Q70551191 | ||
| Surface thiols of human lymphocytes and their changes after in vitro and in vivo activation | Q71802272 | ||
| Prophylactic fibrinolysis through selective dissolution of nascent clots by tPA-carrying erythrocytes | Q73621576 | ||
| Glycolipid-anchored IL-12 expressed on tumor cell surface induces antitumor immune response | Q74130284 | ||
| The CD16-/CD56bright subset of NK cells is resistant to oxidant-induced cell death | Q80582142 | ||
| Combinatorial design of biomaterials for drug delivery: opportunities and challenges | Q81801729 | ||
| Surface functionalization of living cells with multilayer patches | Q83653405 | ||
| Bioactive polyelectrolyte multilayers: hyaluronic acid mediated B lymphocyte adhesion | Q84959285 | ||
| Pulmonary thrombosis in the mouse following intravenous administration of quantum dot-labeled mesenchymal cells | Q84959499 | ||
| P433 | issue | 3 | |
| P921 | main subject | nanomaterial | Q967847 |
| P304 | page(s) | 309-325 | |
| P577 | publication date | 2011-06-01 | |
| P1433 | published in | Nano Today | Q3335726 |
| P1476 | title | Enhancing Cell therapies from the Outside In: Cell Surface Engineering Using Synthetic Nanomaterials | |
| P478 | volume | 6 |
Search more.